DE1302712B - - Google Patents
Info
- Publication number
- DE1302712B DE1302712B DENDAT1302712D DE1302712DA DE1302712B DE 1302712 B DE1302712 B DE 1302712B DE NDAT1302712 D DENDAT1302712 D DE NDAT1302712D DE 1302712D A DE1302712D A DE 1302712DA DE 1302712 B DE1302712 B DE 1302712B
- Authority
- DE
- Germany
- Prior art keywords
- hespendin
- water
- theophylline
- rutin
- formaldehyde
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 14
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 229940081967 Rutin Drugs 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 229930002876 rutin Natural products 0.000 claims description 8
- 235000005493 rutin Nutrition 0.000 claims description 8
- 229960004555 rutoside Drugs 0.000 claims description 8
- IKGXIBQEEMLURG-BKUODXTLSA-N Rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims description 7
- 229960000278 Theophylline Drugs 0.000 claims description 7
- 150000001412 amines Chemical class 0.000 claims description 4
- 239000007859 condensation product Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- -1 dimethylamino, diethylamino, dibutylamino, N-methylaminoethanol Chemical compound 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 3
- 229940025878 Hesperidin Drugs 0.000 description 3
- QUQPHWDTPGMPEX-YEDPJISVSA-N Hesperidin Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C[C@@H](c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 QUQPHWDTPGMPEX-YEDPJISVSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 230000004856 capillary permeability Effects 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 2
- 206010034754 Petechiae Diseases 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 210000001736 Capillaries Anatomy 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 206010018987 Haemorrhage Diseases 0.000 description 1
- 231100000614 Poison Toxicity 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- PYHRZPFZZDCOPH-UHFFFAOYSA-N amphetamine sulfate Chemical compound OS(O)(=O)=O.CC(N)CC1=CC=CC=C1.CC(N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding Effects 0.000 description 1
- 231100000319 bleeding Toxicity 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 125000004915 dibutylamino group Chemical group C(CCC)N(CCCC)* 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/06—Benzopyran radicals
- C07H17/065—Benzo[b]pyrans
- C07H17/07—Benzo[b]pyran-4-ones
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
©le^rfindung betrifft em Verfahren zur Herstellung doshchen Hesperidin-Molekularverbindunr allgemeinen FormelThe invention relates to a manufacturing process doshchen hesperidin molecular compound general formula
Am — CH2 — Hespendm — XAm - CH 2 - Hespendm - X
in der Am den Dimethylamine-, Diathylammo-, Dibutylamino-, N-Methylammoathanol- oder Dia thanolaminorest und X den Ascmyl-, Theophyllinyl- oder Rutmylrest bedeutetin the Am den Dimethylamine-, Diethylammo-, Dibutylamino-, N-methylammoethanol or diethanolamino radical and X is the ascmyl, theophyllinyl or rutmyl radical
Es wurde gefunden, daß diese Verbindungen die Kapillarpermeabihtat verbessern sowie herzwirksam sind, indem sie den Coronardurchfluß steigern und hierin gegenüber bekannten vergleichbaren Verbindungen eine bessere Wirkung aufweisen, wie die folgenden Vergleichsversuche zeigenIt has been found that these compounds improve capillary permeability as well as being cardiac output by increasing coronary flow and herein over known comparable compounds have a better effect like the following Show comparative tests
Hierbei wurde die Kapillarresistenz an Wistarratten
in der Weise bestimmt, daß, beginnend mit einem Vakuum von 180 mm, alle 10 Sekunden das Vakuum
um 20 mm vermindert wurde Sobald durch das Saugrohr eine petechiale Hautblutung erkennbar war,
wurde das entsprechende Vakuum als Maß der Kapillarresistenz registriert An einem Tier wurden
jeweils drei Messungen im Abstand von etwa 10 mm
vorgenommen Darauf wurde das arithmetische Mittel gebildet (nach der von E Massaraniin Farmaco
Pavia 12, 691 [1957]), beschriebenen verbesserten Methode)
Bei gesunden Wistarratten wurden petechiale BIutungen
bei Verminderung des Druckes zwischen 1 und 10 mm beobachtet, im Mittel bei 6,5 mm Nach
4wochiger Behandlung mit einer Vitamin P-freien
Diät traten bei etwa 60% der Tiere bereits Petechien
bei 180 mm auf Die Versuche wurden nur mit Tieren
durchgeführt, bei denen bereits bei einem Vakuum von
180 mm Petechien festgestellt werden konnten Diese Tiere erhielten daraufhin 3 Tage lang taglich einmal
(um 9 Uhr) die Testsubstanz per Magensonde verabreicht 2 Stunden nach der dritten Verabreichung
wurde die Kapillarpermeabihtat erneut geprüft Als Maß fur den therapeutischen Effekt wurde der "Wert
(ED50) festgelegt, bei dem das Vakuum bis zum Auftreten
von Petechien von 180 mm (Wert fur geschadigte Tiere) um 50 mm vermindert werden mußte Bei
ji-Ascin und 6-Diathylaminomethylhesperidin wurde
ein therapeutischer Effekt selbst bei Verabreichung einer Dosis von 50% der DL50 nicht beobachtet In
der folgenden Tabelle smd die erhaltenen Ergebnisse zusammengestelltThe capillary resistance of Wistar rats was determined in such a way that, starting with a vacuum of 180 mm, the vacuum was reduced by 20 mm every 10 seconds Three measurements were made on each animal at a distance of about 10 mm. The arithmetic mean was then formed (according to the improved method described by E Massaraniin Farmaco Pavia 12, 691 [1957]))
In healthy Wistar rats, petechial bleeding was observed when the pressure was reduced between 1 and 10 mm, on average at 6.5 mm only carried out with animals in which petechiae could already be detected at a vacuum of 180 mm.These animals were then given the test substance once a day for 3 days (at 9 o'clock) by gastric tube 2 hours after the third administration, the capillary permeability was checked again as a measure The value (ED 50 ) was established for the therapeutic effect, at which the vacuum had to be reduced by 50 mm from 180 mm (value for damaged animals) to the appearance of petechiae Not observed even when a dose of 50% of the DL 50 was administered . The following table shows the results obtained compiled
Ratte, peroralDL 50 in mg / kg
Rat, perorally
Aus den gefundenen Werten geht hervor, daß /9-Äscm im Tierversuch oral wirkungslos ist, und zwar wegen semer bekannten Nichtresorbierbarkeit, wahrend die geprüften Hespendin-Molekularverbindungen (Beispiele 2 und 3) eine bessere Wirksamkeit als entsprechende Rutin-Molekularverbmdungen aufweisen The values found show that / 9-Åscm has no oral effect in animal experiments, and because of its well-known non-resorbability, while the tested hespendin molecular compounds (Examples 2 and 3) have a better effectiveness than corresponding rutin molecular compounds
Ferner wurde die coronardurchblutende Wirkung in Anlehnung an die Methode von Langendorff (Pflugers Archiv fur experimentelle Pharmakologie, Bd 61 [1895], S 219) in der heute allgemein gültigen und üblichen Form durchgeführt und dabei der Coionardurchfluß, die Kontraktionsamphtude, die Herzfrequenz und die Wirkungsdauer nach s c Injektion der Substanzen gemessenFurthermore, the coronary blood flow effect was based on the method of Langendorff (Pflugers Archiv fur experimental Pharmakologie, Vol. 61 [1895], p. 219) in the generally valid today and usual form carried out and thereby the Coionar flow, the contraction amphetus, the Heart rate and duration of action after s c injection of the substances measured
Die DL50 wurde nach der Methode von L 11 c hfield und W11 c ο χ ο η (Journal of Pharmacology and Experimental Therapeutics, Bd 96 [1948], S 99) subcutan an weißen Mausen bestimmt Die erhaltenen Ergebnisse sind in der folgenden Tabelle zusammengestellt The DL 50 was determined subcutaneously on white mice by the method of L 11 c hfield and W11 c ο χ ο η (Journal of Pharmacology and Experimental Therapeutics, Vol 96 [1948], p. 99). The results obtained are summarized in the following table
Substanzsubstance
Mdximalwirkung auf das Langendorffherz des MeerschweinchensMaximum effect on the Langendorff heart of the guinea pig
Dosis mg
InjektionDose mg
injection
C oronardurchfluß Coronary flow
Amplitude
%amplitude
%
Frequenz
%frequency
%
Wirkungsdauer,
MinutenDuration of action,
Minutes
TheophyllinTheophylline
6-Diathylaminomethylhesperidin
6-Diathylaminomethylhespendintheophylhn
(Beispiel 1)6-diethylaminomethyl hesperidin
6-diethylaminomethylhespendintheophylhn (example 1)
200
1800200
1800
14001400
0,70.7
56
056
0
186186
28
028
0
18
018th
0
2
02
0
Fortsetzungcontinuation
durchfluß
%Coronary
flow
%
%frequency
%
dauer,
MinutenEffect
duration,
Minutes
InjektionDose mg
injection
%amplitude
%
Aus den gefundenen Werten ist ersichtlich, daß 6-Diathylaminomethylhespendin zwar sehr gering giftig ist, aber auf den Coronardurchfluß kerne Wirkung besitzt Dagegen ist das 6-Diathylamrnomethylhesperidin-theophylhn (Beispiel 1) nicht nur wesentlich geringer giftig als Theophyllin, sondern auch bedeutend starker und langer wirksam als dieses, wobei die oft unerwünschte Steigerung der Herzfrequenz praktisch ausgeschaltet ist, und gegenüber dem bekannten 6-Diathylaminomethylrutintheophyllin ist es gleichfalls besser wirksamFrom the values found it can be seen that 6-diethylaminomethylhespendin is very low is poisonous, but has no effect on coronary flow In contrast, 6-diethylamine-methyl hesperidin-theophylhn is possessed (Example 1) not only significantly less toxic than theophylline, but also significantly stronger and longer effective than this, the often undesirable increase in heart rate being practical is switched off, and compared to the well-known 6-diethylaminomethylrutintheophylline it is also more effective
Die wasserlöslichen Hespendin-Molekularverbindüngen der oben angegebenen allgemeinen Formel werden dadurch hergestellt, daß man in an sich bekannter Weise entweder Hespendin, das Amin Am und Formaldehyd sowie Äscin, Theophyllin oder Rutin m molekularen Mengen in Gegenwart von Wasser als Losungs- oder Verdünnungsmittel umsetzt oder das aus Hespendin mit dem Amin Am und Formaldehyd hergestellte Kondensationsprodukt Am — CH2 — Hespendin mit Ascm, Theophyllin oder Rutin in Gegenwart von Wasser umsetzt, wobei Am die oben angegebene Bedeutung besitztThe water-soluble hespendin molecular compounds of the general formula given above are prepared by reacting in a manner known per se either hespendin, the amine Am and formaldehyde as well as ascine, theophylline or rutin in molecular amounts in the presence of water as a solvent or diluent, or that condensation product Am - CH 2 - hespendin prepared from hespendin with the amine Am and formaldehyde is reacted with Ascm, theophylline or rutin in the presence of water, Am having the meaning given above
23 g Hespendin werden in 50 ml Wasser suspendiert und dann 5 ml Diathylamin und 5 ml Formaldehyd (37%ig) hinzugegeben Daraufhin werden 6 g Theophyllin hinzugefügt, und das Ganze wird zum Sieden erhitzt Nach kuizer Zeit geht alles in Losung Die gelborange Losung wird anschließend noch 15 Minuten zum Sieden erhitzt, dann etwas abkühlen gelassen und mit 100 ml Isopropanol versetzt Dabei fallt ein prachtig gefärbtes gelboranges Knstallmehl aus, welches abgesaugt und mit wenig Isopropanol gewaschen wird Die Ausbeute an 6-Diathylaminomethylhespendui-theophylun betragt 26 g Die Verbindung schmilzt ab 2700C unter Zersetzung Sie ist leicht löslich in Wasser und unlöslich in Alkoholen23 g of hespendin are suspended in 50 ml of water and then 5 ml of diethylamine and 5 ml of formaldehyde (37%) are added. 6 g of theophylline are then added and the whole thing is heated to the boil Heated to boiling for a further 15 minutes, then allowed to cool slightly and mixed with 100 ml of isopropanol.A splendidly colored, yellow-orange poplar flour precipitated out, which was filtered off with suction and washed with a little isopropanol 0 C with decomposition It is easily soluble in water and insoluble in alcohol
6.6 g Hespendin werden mit 2 ml Diathylamin und 2 ml Formahn in Wasser zum Sieden erhitzt, wobei sich alles mit gelboranger Farbe auflost Dann werden 11g /3-Ascin eingetragen, welches sich sofort lost Das Ganze wird hierauf noch 10 Minuten zum Sieden erhitzt, abkühlen gelassen und nut 20 ml Isopropanol versetzt Dabei fallt 6-Diathylaminomethylhesperidinascinat als gelboranges Pulver aus, das sich sehr leicht unter Schäumen in Wasser lost Die Ausbeute betragt 15 g Die Verbindung schmilzt ab 21O0C unter Zersetzung 6.6 g of hespendin are heated to boiling with 2 ml of dietamine and 2 ml of Formahn in water, and everything dissolves with a yellow-orange color. Then 11 g / 3-Ascin are added, which dissolves immediately left and nut 20 ml of isopropanol in this case falls 6-Diathylaminomethylhesperidinascinat of as a yellow-orange powder, which is very easy to foam in water lost the yield is 15 g the compound melts at 21O 0 C with decomposition
7 g 6-N-Methyl-N-athanolamino-methy]-hesperidin, die aus Hespendin, Formaldehyd und N-Methylathanol hergestellt worden smd, werden in 30 ml Wasser warm (50° C) gelost In die warme Losung werden 6 g Rutin eingetragen, und das Ganze wird zum Sieden erhitzt, so daß das Rutin in Losung geht Anschließend wird die Mischung erkalten gelassen und mit 20 ml Isopropanol versetzt Dabei fallt das 6-Methyl-N-athanolaminhespendinrutin als gelboranges Pulver aus Die Ausbeute betragt 12 g Die Verbindung schmilzt ab 2700C unter Zersetzung7 g of 6-N-methyl-N-athanolamino-methy] hesperidin, which have been prepared from hespendin, formaldehyde and N-methylethanol, are dissolved in 30 ml of warm water (50 ° C.). 6 g of rutin are dissolved in the warm solution entered, and the whole thing is heated to boiling so that the rutin goes into solution. The mixture is then allowed to cool and 20 ml of isopropanol are added melts from 270 ° C. with decomposition
Claims (1)
Publications (1)
Publication Number | Publication Date |
---|---|
DE1302712B true DE1302712B (en) |
Family
ID=621462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DENDAT1302712D Pending DE1302712B (en) |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE1302712B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020188689A (en) * | 2019-05-20 | 2020-11-26 | 東洋精糖株式会社 | INHIBITOR OF TOXIC AGEs FORMATION |
-
0
- DE DENDAT1302712D patent/DE1302712B/de active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020188689A (en) * | 2019-05-20 | 2020-11-26 | 東洋精糖株式会社 | INHIBITOR OF TOXIC AGEs FORMATION |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AT391864B (en) | METHOD FOR PRODUCING NEW 5-PYRIMIDINE CARBOXAMIDES AND THEIR ADDITIONAL SALTS | |
DE1595876A1 (en) | Process for the preparation of aminomethyl derivatives of Rifamycin SV | |
DE2458638A1 (en) | PROPIOPHENONE DERIVATIVES AND THEIR PRODUCTION | |
DE1302712B (en) | ||
DE1545772B1 (en) | 7- (3'-picolylamino-alkyl) -theophyllins and their nicotinic acid salts | |
DE2432392C3 (en) | Tris (2-hydroxyethyl) ammonium orthocresoxyacetate, process for its production and pharmaceuticals based on it | |
DE2028880C3 (en) | N-Phenylcarbamoyl-3- (ßphenylisopropyl) sydnonunine, process for its preparation and pharmaceuticals | |
DE2835043A1 (en) | BROMHEXIN DERIVATIVES WITH LOWER MUCOLICANT AND COUGH RELEASE EFFECT AND TOXICITY IN COMPARISON OF BROMHEXIN | |
DE2146395C3 (en) | N-p-Toluenesulfonyl-5-methyl-d2 -pyrazoline-1-carbonamide and process for its preparation | |
DE1134071C2 (en) | PROCESS FOR THE PRODUCTION OF NEW DERIVATIVES OF TETRACYCLIN-ANTIBIOTICA | |
AT326127B (en) | PROCESS FOR THE PREPARATION OF NEW QUATERNATED EASTERS OF NICOTINE ACID WITH POLYSACCHARIDES | |
DE2327193C3 (en) | N- (Diethylaminoethyl) -2-methoxy-5methylsulfonylbenzamide, its salts, processes for the preparation of these compounds and medicaments containing these compounds | |
DE2241076B2 (en) | Tetracycline complex and its salts, process for its preparation and pharmaceutical compositions containing this complex | |
DE2247828A1 (en) | SULFAMOYL ANTHRANILIC ACIDS AND THE PROCESS FOR THEIR MANUFACTURE | |
DE1518141C3 (en) | Process for the production of a condensation product from a crude extract from Podophyllum rhizomes with benzaldehyde | |
DE2152059A1 (en) | Alkali salt of carboxylkylglucan and process for its preparation | |
DE2446586A1 (en) | 6-DEOXYTETRACYCLIN DERIVATIVES, THEIR PHARMACEUTICAL SALT, METHOD FOR THEIR MANUFACTURING AND ANTIBIOTIC PREPARATIONS CONTAINING THEM | |
DE1212542B (en) | Process for the preparation of water-soluble diethyl acetals from xanthine derivatives | |
DE2312428A1 (en) | NEW ANDROSTERONE DERIVATIVE, PROCESS FOR ITS MANUFACTURING AND PHARMACEUTICAL COMPOSITIONS | |
DE1289052B (en) | 6,7-Dihydroxycoumarin derivatives substituted in the 4-position, their salts and processes for their preparation | |
CH687001A5 (en) | A pharmaceutical composition for modulating the immune response. | |
DE1138064B (en) | Process for the preparation of 6-acetyl-7, 8-dihydro-3-ethylmorphine | |
DE1182669B (en) | Process for the production of hydrochlorides of basic substituted chromones | |
DE1916693A1 (en) | 9-oxo-10-oxa-9,10-dihydroanthracene, basic - derivatives | |
DE1695998B2 (en) | N HIGH 2, N HIGH 3-DI-SPIRO-TRIPIPERAZINIUM SALT AND METHOD FOR MAKING THEM |